Day: May 13, 2023

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telephone and Data Systems, Inc. (the “Company” or “TDS”) (NYSE: TDS, TDSPrU, TDSPrV) between May 6, 2022 and November 3, 2022, both dates inclusive (the “Class Period”), of the important July 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased TDS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TDS class action, go to https://rosenlegal.com/submit-form/?case_id=15807 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Company and its subsidiary, United States Cellular Corporation (“UScellular”), made false and/or misleading statements and/or failed to disclose that: (1) defendants had no reason to believe UScellular’s “free upgrade” promotional activity, which was tested and trialed during the second quarter of 2022, was effective at reducing the Company’s postpaid churn rate as they represented to investors, as opposed to merely adding new postpaid subscribers, when its churn rate was actually increasing or remaining constant over most quarters in the class period; (2) UScellular was not making progress with respect to its churn rate, as it represented to investors; (3) UScellular was not in fact balancing its promotional activity and its profitability; (4) due to extreme competition among postpaid carriers, UScellular did not have the flexibility to offset the costs from widespread, expensive promotions with price increases; and (5) as a result of the Companies’ decision for UScellular to continue engaging in heavy promotions to address its postpaid subscriber churn rate despite any lack of positive impact on churn rate, UScellular’s profitability substantially declined. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TDS class action, go to https://rosenlegal.com/submit-form/?case_id=15807 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8838498

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15-19. He will deliver a keynote presentation on “The State of the Science in Disease Modeling Across Diverse Indications” on May 15 at 11AM at the Hynes Convention Center and join in an interactive discussion on May 15 at 12:45PM.

In his presentation, Dr. Zhavoronkov will make the first announcement of peptide-based drug design strategies and Generative Biologics, a new engine that belongs to the company’s end-to-end AI-driven drug discovery platform Pharma.AI that leverages hundreds of millions of biological data points, machine learning algorithms, and generative biology models to build and design polypeptides from scratch.

A team of expert scientists are developing Pharma.AI at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.

“We are at an exciting moment in the history of generative AI in drug discovery,” says Zhavoronkov. “Thanks to years of accumulated data and technological advances in generative AI, we can find targets and design new small molecules for hard-to-treat diseases with incredible speed and efficiency working in close partnership with pharmaceutical companies. We look forward to using generative AI to explore diverse drug development strategies.”

Insilico Medicine was one of the first companies to use generative adversarial autoencoders for de-novo drug discovery. In 2016, the Company introduced the earliest iternation of its generative biology tool for identifying novel targets with a publication in Nature Communications. Another publication followed in Oncotarget, demonstrating how Insilico could employ generative algorithms with reinforcement learning to design novel small molecules with predefined and optimized properties. By 2018, Insilico integrated generative biology and chemistry approaches into the commercially available Pharma.AI platform that accelerates the process of lead discovery from years to days, and is currently being utilized by 11 of 20 top pharmaceutical companies.

The Company has also utilized the platform to develop its own robust pipeline of assets, including two drugs – for idiopathic pulmonary fibrosis and COVID-19 – currently in clinical trials and many potentially best-in-class and first-in-class assets in preclinical stages of development available for licensing. In total, Insilico has 31 programs across 29 targets, including in fibrosis, oncology, immunology, and central nervous system disorders.

Zhavoronkov says PEGS, the world’s largest gathering of protein engineering and biotherapeutics experts, is the perfect setting for announcing the latest developments to Insilico’s platform. “We were instrumental in the early development of generative biology and generative chemistry, and now we’re advancing AI-designed drugs into clinical trials. It is truly a pivotal moment.”

About Insilico Medicine

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. In early 2023, the Company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the region’s largest AI-powered biotechnology research center. The R&D hub brings together global talent in artificial intelligence and software development to expand the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support the digital transformation of healthcare in the region.

For more information, visit www.insilico.com

Attachment

• Alex Zhavoronkov, PhD presents at PEGS

Brita Belli
Insilico Medicine
475-225-0843
brita@insilico.com

GlobeNewswire Distribution ID 8838633